Pharmaceutical Technology
MARCH 9, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: In-vitro T-cell activation. Immatics is the leading patent filer in in-vitro T-cell activation.
Pharma Mirror
AUGUST 30, 2022
The Test Bed utilizes Cytocentric principles, an innovative philosophy of putting the needs of the vulnerable cells front and center while growing and manipulating them in vitro. The post Testing Facility Called “Game Changer” in Regenerative Medicine appeared first on Pharma Mirror Magazine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 19, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AstraZeneca ’s Evusheld (formerly AZD7442) for Covid-19 in the European Union (EU). The combination therapy was also found to retain in vitro neutralisation of SARS-CoV-2 virus’ Omicron BA.5
Pharmaceutical Technology
MAY 4, 2023
The approval allows KALYDECO to be used in infants who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to the therapy, on the basis of clinical and/or in vitro assay results. The medicine is currently available for use in more than 30 countries.
Pharmaceutical Technology
APRIL 27, 2023
The treatment is now indicated for CF patients with a minimum of one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, or with a mutation in the CFTR gene that responds to Trikafta based on in vitro data. It was previously approved to treat CF in children aged between six and 11 years.
Scienmag
NOVEMBER 17, 2020
Researchers at Karolinska Institutet in Sweden report promising results from an in vitro combination therapy against COVID-19. Credit: Martin Stenmark.
Medical Xpress
MAY 16, 2023
That was the case when Thilini Gamage was to carry out one of the studies in her doctoral work with Professor Eirik Frengen at the Institute of Clinical Medicine, University of Oslo. They study gene variation and mutations that cause rare genetic diseases. A mutation is a permanent change in the genetic material.
Expert insights. Personalized for you.
130 
Let's personalize your content